Brokerages Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) PT at $20.40

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been assigned a consensus rating of "Buy" from the six ratings firms that are currently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $20.40.

A number of equities research analysts recently commented on ARTV shares. Wedbush restated an "outperform" rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday, March 25th. Cantor Fitzgerald lowered their target price on Artiva Biotherapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a research note on Tuesday, March 25th. Needham & Company LLC reiterated a "buy" rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday, April 8th. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Artiva Biotherapeutics in a research report on Wednesday, March 26th.

Artiva Biotherapeutics Trading Down 1.4 %

Shares of ARTV traded down $0.03 during mid-day trading on Friday, reaching $2.15. The company had a trading volume of 16,825 shares, compared to its average volume of 174,173. The company's 50-day moving average is $3.24 and its 200-day moving average is $6.93. Artiva Biotherapeutics has a twelve month low of $1.78 and a twelve month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.15). On average, sell-side analysts predict that Artiva Biotherapeutics will post -4.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Franklin Resources Inc. acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth about $7,435,000. Geode Capital Management LLC boosted its position in Artiva Biotherapeutics by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 315,758 shares of the company's stock valued at $3,184,000 after purchasing an additional 6,828 shares during the last quarter. Northern Trust Corp grew its stake in Artiva Biotherapeutics by 3.8% in the fourth quarter. Northern Trust Corp now owns 117,112 shares of the company's stock valued at $1,180,000 after purchasing an additional 4,335 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Artiva Biotherapeutics by 8.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company's stock worth $439,000 after purchasing an additional 3,233 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Artiva Biotherapeutics by 250.7% during the 4th quarter. JPMorgan Chase & Co. now owns 37,619 shares of the company's stock worth $379,000 after purchasing an additional 26,893 shares during the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.